Lyvgen was founded in 2016 by Jieyi Wang, Ph.D, who serves as the Chairman and CEO. Previously, Dr. Wang worked at Abbott/AbbVie for 22 years in Oncology R&D with extensive experience in new drug discovery, cancer biology and immunotherapy. Lyvgen has completed its Series A funding through Morningside Venture. Recently Lyvgen closed a USD $30 million Series B funding round. 6 Dimensions Capital led this round of financing, with participation from Winfair Global, Runling Capital and existing Series A investor Morningside Ventures.
礼进生物于2016年在上海浦东张江高科技园区注册成立。生物药物研发专家王结义博士为公司创始人并担任CEO,领导管理和运营。之前王结义博士在雅培/艾伯维工作二十二年,有丰富的抗癌新药及肿瘤免疫研发经验。礼进生物A 轮融资由晨兴创投完成,公司最近又完成3000万美元的B轮融资,本次融资由通和毓承领投,其他投资方包括Winfair Global和润瓴资本,原有投资者晨兴创投也参与了本轮投资。